RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

Exclusion Criteria

• •An individual who meets any of the following criteria will be excluded from participation in this study. Refer to appendices for additional appendix-level criteria:
• •1. Known active acute SARS-CoV-2 infection ≤ 4 weeks from consent
• •2. Known severe anemia, defined as \< 8 g/dL
• •3. Meeting the following symptom cluster exclusion for all eligible clusters\*:
• •a. Cognitive dysfunction: known stroke that resulted in cognitive impairment within 3 months of enrollment b. Autonomic dysfunction: atrial fibrillation or significant cardiac arrhythmia, more than moderate alcohol consumption\*\*, pre-existing sustained severe hypertension (BP\> 180/110 mmHg in the sitting position) c. Exercise intolerance: i. any of the following within 4 weeks of consent - an acute myocardial infarction or unstable angina, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, acute myocarditis or pericarditis, uncontrolled acutely decompensated heart failure (acute pulmonary edema), acute pulmonary embolism, suspected dissecting aneurysm, severe hypoxemia at rest, any acute or chronic disorder that may affect exercise performance ii. if the participant is aggravated by exercise (e.g., infection, thyrotoxicosis, unable to cooperate)
• •\*\* Defined as greater than 2 drinks a day for men and 1 drink a day for women. A drink is equivalent to 12 ounces of beer (5% alcohol content), 8 ounces of malt liquor (7% alcohol content), 5 ounces of wine (12% alcohol content), 1.5 ounces or a "shot" of 80-proof (40% alcohol content) distilled spirits or liquor (e.g., gin, rum, vodka, whiskey). 21
• •4. Known diagnosis of chronic Lyme disease with persistent symptoms, sequelae, or related therapy
• •5. Any non-marijuana illicit drug use within 30 days of informed consent
• •6. Current or recent use (within the last 14 days) of study intervention\*
• •7. Known allergy/sensitivity or any hypersensitivity to components of the study intervention (s) or control\*
• •8. Known contraindication(s) to study intervention(s),
• •9. Inability to discontinue symptomatic medications for the identified time periods
• •10. Moderate or severe immunocompromised patients, such as those described in the NIH COVID-19 Treatment Guidelines (https://www.covid19treatmentguidelines.nih.gov/ special populations/immunocompromised/)
• •11. Currently enrolled in another clinical trial outside this platform protocol or another study intervention appendix in this platform protocol\*\*\*
• •\*\*\*Participants may re-enroll in the trial for a different study intervention appendix if the participant has completed an appropriate washout period and efficacy has been determined for the appendix in which the participant was previously enrolled.
• •12. Any condition that would make the participant, in the opinion of the investigator, unsuitable for the study
• •* If only one study intervention appendix is open at the time of enrollment. If multiple study intervention appendices are open, a participant may be excluded from any study intervention appendix based on contraindications listed in the study intervention appendix, current use of study intervention, or known allergy/sensitivity/hypersensitivity and still remain eligible for the remaining study intervention appendices.